

NFL BIOSCIENCES SHOWCASES THE RESULTS OF ITS STUDIES TO THE SCIENTIFIC AND PHARMACEUTICAL COMMUNITIES

NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is showcasing the promising scientific results achieved by NFL-101, its drug candidate for smoking cessation, with two initiatives: the submission of a scientific paper and a presentation given at the Society for Research on Nicotine and Tobacco (SRNT) annual conference at the end of March.

Submission of a joint scientific paper from the CEA, Hôpital Européen Georges Pompidou and NFL-Biosciences

Just two months after obtaining the results, the CEA recently submitted a paper on the findings¹ from the study on the mechanism of action of NFL-101 conducted with NFL Biosciences in 2023 to an international scientific journal. The research presented was supplemented with previous work from Hôpital Européen Georges Pompidou (HEGP). This synergy with various prestigious institutions aims to further strengthen the impact and reach of the results obtained. This paper is expected to be published in the spring following its approval by the journal's scientific review committee. This work will then be promoted at future scientific conferences.

Promising results from the PRECESTO study on NFL-101 presented at the SRNT conference

The presentation by Bruno Lafont, Chief Operating Officer and co-founder of NFL Biosciences, made it possible to showcase the PRECESTO clinical trial's promising results to the international scientific community committed to the fight against smoking. The discussions, centered around the ability of NFL-101 to reduce smoking satisfaction, made it possible to further strengthen interactions with researchers and experts in this field and confirmed that NFL-101 is the most innovative smoking cessation drug candidate since the launch of Champix®, 17 years ago.

The 2024 SRNT conference was held in Edinburgh from March 20 to 23, 2024.

About NFL Biosciences

NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.

The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com

Contacts

Bruno Lafont – info@nflbiosciences.com - +33 4 11 93 76 67

Agence Calyptus – nflbiosciences@calyptus.net - +33 1 53 65 68 68

¹ See [press release from January 30, 2024](#).